Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13
- PMID: 20553713
- DOI: 10.1016/j.yexcr.2010.05.024
Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13
Abstract
Human mesenchymal stem cells (hMSCs) are multipotent cells that are found in the bone marrow. Inflammation and tissue damage mobilize MSCs and induce their migration towards the damaged site through mechanisms that are not well defined. Toll-like receptor-9 (TLR9) is a cellular receptor for microbial and vertebrate DNA. Stimulation of TLR9 induces inflammatory and invasive responses in TLR9-expressing cells. We studied here the expression of TLR9 in human MSCs and the effects of synthetic TLR9-agonists on their invasion. Constitutive expression of TLR9 was detected in human MSCs but the expression was suppressed when MSCs were induced to differentiate into osteoblasts. Using standard invasion assays and a novel organotypic culture model based on human myoma tissue, we discovered that stimulation with the TLR9 agonistic, CpG oligonucleotides increased the invasion capacity of undifferentiated MSCs. Simultaneously, an increase in MMP-13 synthesis and activity was detected in the CpG-activated MSCs. Addition of anti-MMP-13 antibody significantly diminished the CpG-induced hMSC invasion. We conclude that treatment with TLR9-ligands increases MSC invasiveness, and this process is at least partially MMP-13-mediated.
2010 Elsevier Inc. All rights reserved.
Similar articles
-
Toll-like receptor 9 in breast cancer.Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014. Front Immunol. 2014. PMID: 25101078 Free PMC article. Review.
-
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.Mol Cancer Res. 2006 Jul;4(7):437-47. doi: 10.1158/1541-7786.MCR-06-0007. Mol Cancer Res. 2006. PMID: 16849519
-
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.Prostate. 2007 May 15;67(7):774-81. doi: 10.1002/pros.20562. Prostate. 2007. PMID: 17373717
-
Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.Mol Cancer Res. 2008 Oct;6(10):1534-43. doi: 10.1158/1541-7786.MCR-07-2005. Mol Cancer Res. 2008. PMID: 18922969
-
Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.Vet Immunol Immunopathol. 2005 Oct 18;108(1-2):11-6. doi: 10.1016/j.vetimm.2005.07.012. Vet Immunol Immunopathol. 2005. PMID: 16098606 Review.
Cited by
-
Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors.Mediators Inflamm. 2013;2013:181020. doi: 10.1155/2013/181020. Epub 2013 Dec 10. Mediators Inflamm. 2013. PMID: 24391353 Free PMC article. Review.
-
Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells.Mol Ther Methods Clin Dev. 2014 Sep;2014(1):14041-. doi: 10.1038/mtm.2014.41. Mol Ther Methods Clin Dev. 2014. PMID: 25279386 Free PMC article.
-
Toll-like receptor 9 in breast cancer.Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014. Front Immunol. 2014. PMID: 25101078 Free PMC article. Review.
-
Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.Oncoimmunology. 2015 May 22;4(6):e1002726. doi: 10.1080/2162402X.2014.1002726. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155410 Free PMC article.
-
Organotypic three-dimensional assays based on human leiomyoma-derived matrices.Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):20160482. doi: 10.1098/rstb.2016.0482. Philos Trans R Soc Lond B Biol Sci. 2018. PMID: 29158312 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources